<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="49">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02899091</url>
  </required_header>
  <id_info>
    <org_study_id>CHA-PAD-101</org_study_id>
    <nct_id>NCT02899091</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of CB-AC-02 in Patients With Alzheimer's Disease</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase I / IIa Clinical Trial for Evaluation of Safety and Potential Therapeutic Effect After Transplantation of CB-AC-02 in Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHABiotech CO., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHABiotech CO., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the safety and the potential therapeutic effects of&#xD;
      CB-AC-02 Intravenous Transplantation in patients with Alzheimer' disease comprised of 2&#xD;
      treatment cohorts:&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>48 weeks</time_frame>
    <description>Number of subjects with treatment-related adverse events.&#xD;
The safety and tolerability of treatment with CB-AC-02 will be assessed by analysis of adverse events, abnormal findings on physical examinations, standard laboratory tests.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from the baseline in ADAS-Cog (Azheimer's disease Assessment Scale - Congintive Subscale) Score</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from the baseline in K-MMSE (Korean-Mini Mental Status Examination) Score</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from the baseline in GDS (Global Deterioration Scale)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from the baseline in CDR (Clinical Dementia Rating) Score</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from the baseline in K-IADL (Korean Instrumental Activities of Daily Living) Score</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from the baseline in CGA-NPI (Caregiver Administered-Neuropsychiatric Inventory) Score</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CIBIC (Clinician Interview Based Impression of Change)-plus</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from the baseline in SF-36</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Amyloid Beta and Tau amount (pg/mL) in CSF (Cerebrospinal fluid)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Brain MRI (Magnetic Responance imaging)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from the baseline of CMRglc (cerebral metabolic rate for glucose ) analyzed with SPM (statistical parametric mapping) with Brain FDG PET imaging</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from the baseline of Amyloid amount analyzed with SPM (statistical parametric mapping) with amyloid PET imaging</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of band power in qEEG (Quantitative electroencephalography)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>CB-AC-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with Alzheimer's disease Intervention: CB-AC-02</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects with Alzheimer's disease Intervention: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CB-AC-02</intervention_name>
    <description>Stage1:&#xD;
① Group1: CB-AC-02, 2.0 x 10^8 cells on day 0&#xD;
② Group2: CB-AC-02, 2.0 x 10^8 cells, on day 0 and on week 4 (repeated injection)&#xD;
Stage2&#xD;
① Arm1: K-MMSE 20~26 CB-AC-02, 2.0 x 10^8 cells on day 0 and on week 4 (repeated injection)&#xD;
② Arm2: K-MMSE 10~19 CB-AC-02, 2.0 x 10^8 cells on day 0 and on week 4 (repeated injection)</description>
    <arm_group_label>CB-AC-02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Stage2:&#xD;
Placebo on day 0 and on week 4 (repeated injection)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Korean male or female at 50+ years of age at the time of screening visit&#xD;
&#xD;
          2. Diagnosis of Probable Alzheimer disease (probable AD) according to NINCDS-ADRDA&#xD;
             criteria at Screening visit&#xD;
&#xD;
          3. Positive for Amyloid on amyloid-ligand PET&#xD;
&#xD;
          4. A subject with the imaging findings of Alzheimer's disease as confirmed by MRI or PET&#xD;
&#xD;
               -  Presence of brain atrophy on brain MRI by visual assessment&#xD;
&#xD;
               -  Presence of reduced brain glucose metabolism in bilateral temporal-parietal lobe&#xD;
                  on FDG-PET&#xD;
&#xD;
          5. Korea Mini-Mental State Examination (KMMSE) score of 10-26 at time of screening visit&#xD;
&#xD;
          6. Presence of caregiver who can provide information on the subject's condition&#xD;
&#xD;
          7. Subject who has been taking stable dose of Alzheimer medication for last 2 months or&#xD;
             more&#xD;
&#xD;
          8. Subject who is informed of the clinical trial and signs a consent form (if unable to&#xD;
             sign, a consent from a legally acceptable representative is required)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concurrent Dementia as a result of other disorders [i.e. infectious disease of the&#xD;
             central nervous system such as HIV, syphilis, head injury, Creutzfeld-Jacob disease,&#xD;
             Picks disease, Huntington's disease, Parkinson's disease, other subdural hematoma,&#xD;
             hydrocephalus and structural brain lesions, drug addiction, alcoholism, substance&#xD;
             abuse, thyroid disease, parathyroid disease, vitamins and other nutritional&#xD;
             deficiencies and vascular etc.]&#xD;
&#xD;
          2. Subject with vascular dementia as determined by the clinical criteria of DSM-IV and&#xD;
             the imaging criteria of Erkinkuntii&#xD;
&#xD;
          3. Subject with severe white matter hyperintensities (i.e. ≥ 25mm of the deep white&#xD;
             matter and ≥ 10mm of the periventricular capping/banding in lengths)&#xD;
&#xD;
          4. Abnormal laboratory findings at screening visit:&#xD;
&#xD;
             A. ALT or AST ≥ 2.5 times the upper limit of normal value&#xD;
&#xD;
             B. Serum creatinine ≥ 1.5 times the upper limit of normal value&#xD;
&#xD;
             C. Total bilirubin ≥ 2 times the upper limit of normal value&#xD;
&#xD;
             D. Total WBC counts &lt; 3,000/㎣&#xD;
&#xD;
             E. Hemoglobin &lt;9.5g/dL in men or &lt;9.0g/dL in women&#xD;
&#xD;
             F. Platelet count &lt; 150,000/㎣ at screening visit&#xD;
&#xD;
             G. PT (INR) ≥ 1.5 or aPTT ≥ 1.5 times the upper limit of normal value&#xD;
&#xD;
          5. Subjects who are positive for HIV, syphilis or active HBV, HCV infection&#xD;
&#xD;
          6. Subjects in poor medical condition or subjects with severe cardiovascular,&#xD;
             gastrointestinal, pulmonary or endocrinologic disease A. Suspected active active lung&#xD;
             disease on chest X-ray at screening visit B. Diagnosis of cancer (except for the&#xD;
             subjects who remains in complete remission for 5 years or more )&#xD;
&#xD;
          7. Subject with concurrent unstable psychiatric disorder (i.e. severe depression, or&#xD;
             schizophrenia, or bipolar disorder, etc)&#xD;
&#xD;
          8. Pregnant or lactating women&#xD;
&#xD;
          9. Women of childbearing age who reject to practice contraception with one of the&#xD;
             following methods&#xD;
&#xD;
               -  Use a condom&#xD;
&#xD;
               -  Use of contraceptive (oral, dermal, or injectable)&#xD;
&#xD;
               -  Use an intra-uterine contraceptive device&#xD;
&#xD;
         10. Subjects with a history of alcohol abuse (&gt;30g/day) or drug abuse&#xD;
&#xD;
         11. Subjects who cannot undergo any of the tests performed in this clinical trial (for&#xD;
             example, MRI, CT, PET, CSF study)&#xD;
&#xD;
         12. Subjects with known allergies to protein products (Bovine serum), antibiotics&#xD;
             (gentamycin) or DMSO&#xD;
&#xD;
         13. Subjects whom the principal investigator considers inappropriate for participation in&#xD;
             theis study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hye Sun Kim</last_name>
    <phone>+82-31-881-7431</phone>
    <email>goldfish79@chamc.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bundang Medical Center</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HyunSook Kim, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 2, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2016</study_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Mesenchymal Stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

